WO2018081202A1 - Marqueurs du syndrome de fatigue chronique - Google Patents

Marqueurs du syndrome de fatigue chronique Download PDF

Info

Publication number
WO2018081202A1
WO2018081202A1 PCT/US2017/058189 US2017058189W WO2018081202A1 WO 2018081202 A1 WO2018081202 A1 WO 2018081202A1 US 2017058189 W US2017058189 W US 2017058189W WO 2018081202 A1 WO2018081202 A1 WO 2018081202A1
Authority
WO
WIPO (PCT)
Prior art keywords
cfs
evs
subject
biomarker
circulating
Prior art date
Application number
PCT/US2017/058189
Other languages
English (en)
Inventor
Akiko Eguchi
Ariel E. Feldstein
Yasuyoshi Watanabe
Sanae Fukuda
Hirohiko KURASTUNE
Original Assignee
The Regents Of The University Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of California filed Critical The Regents Of The University Of California
Publication of WO2018081202A1 publication Critical patent/WO2018081202A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La présente invention concerne des procédés de détection, de surveillance, d'évaluation et de traitement du syndrome de fatigue chronique (CFS) et de maladies ou d'états associés chez un sujet comprenant la mesure de la quantité de vésicules extracellulaires (EV) dans le prélèvement corporel, ou le niveau d'expression ou l'activité d'au moins un biomarqueur associé au CFS exprimé ou détecté dans les EV. Le niveau accru d'EV dans le prélèvement corporel et/ou l'expression ou le niveau de détection accru(e) du biomarqueur d'intérêt sont corrélés au niveau de gravité du CFS.
PCT/US2017/058189 2016-10-25 2017-10-25 Marqueurs du syndrome de fatigue chronique WO2018081202A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662412368P 2016-10-25 2016-10-25
US62/412,368 2016-10-25

Publications (1)

Publication Number Publication Date
WO2018081202A1 true WO2018081202A1 (fr) 2018-05-03

Family

ID=62025437

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/058189 WO2018081202A1 (fr) 2016-10-25 2017-10-25 Marqueurs du syndrome de fatigue chronique

Country Status (1)

Country Link
WO (1) WO2018081202A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021133669A1 (fr) * 2019-12-23 2021-07-01 The Jackson Laboratory Procédés et systèmes de diagnostic de l'encéphalomyélite myalgique/du syndrome de fatigue chronique (me/sfc) à partir de marqueurs immunitaires

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150366897A1 (en) * 2013-02-12 2015-12-24 Reneuron Limited STEM CELL MICROPARTICLES AND miRNA
WO2016023077A1 (fr) * 2014-08-15 2016-02-18 Griffith University Marqueurs biologiques

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150366897A1 (en) * 2013-02-12 2015-12-24 Reneuron Limited STEM CELL MICROPARTICLES AND miRNA
WO2016023077A1 (fr) * 2014-08-15 2016-02-18 Griffith University Marqueurs biologiques

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BRENU ET AL.: "Cytotoxic lymphocyte microRNAs as prospective biomarkers for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis", JOURNAL OF AFFECTIVE DISORDERS, vol. 141, no. 2, 10 December 2012 (2012-12-10), pages 261 - 269, XP055479399 *
NAKATOMI ET AL.: "Neuroinflammation in Patients with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis: An C-(R)- PK 11195 PET Study", J NUCL MED, vol. 55, no. 6, March 2014 (2014-03-01), pages 945 - 950, XP055479406 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021133669A1 (fr) * 2019-12-23 2021-07-01 The Jackson Laboratory Procédés et systèmes de diagnostic de l'encéphalomyélite myalgique/du syndrome de fatigue chronique (me/sfc) à partir de marqueurs immunitaires
EP4081958A4 (fr) * 2019-12-23 2024-01-10 Jackson Lab Procédés et systèmes de diagnostic de l'encéphalomyélite myalgique/du syndrome de fatigue chronique (me/sfc) à partir de marqueurs immunitaires

Similar Documents

Publication Publication Date Title
JP6404208B2 (ja) 特発性肺線維症の予後予測、診断および処置の方法
US10017821B2 (en) Biomarkers for diagnosing ischemia
CN113286895A (zh) 用于诊断和治疗脑疾患，尤其是认知障碍的长的非编码RNA(lncRNA)
EP3350345B1 (fr) Biomarqueurs pour l'insuffisance cardiaque
EP3314014A1 (fr) Interactions chromosomiques épigénétiques
AU2014207321A1 (en) Anti-TNF and anti-IL17 combination therapy biomarkers for inflammatory disease
O’Connell et al. Peripheral blood AKAP7 expression as an early marker for lymphocyte-mediated post-stroke blood brain barrier disruption
US20180298455A1 (en) Risk stratification in influenza
US20190317098A1 (en) Composition for diagnosis of diseases
JP2005510251A5 (fr)
Qin et al. Preliminary Study of hsa-mir-626 Change in the Cerebrospinal Fluid in Parkinson's Disease
WO2014118550A1 (fr) Biomarqueurs de maladies auto-immunes et/ou chroniques associées à l'inflammation d'une articulation
WO2022031920A2 (fr) Panneau de biomarqueur de maladie rénale de stade terminal
Tan et al. Evaluating the performance of four assays for carrier screening of spinal muscular atrophy
WO2020218465A1 (fr) Procédé de diagnostic de l'endométriose, procédé de surveillance d'état de maladie et trousse
WO2018081202A1 (fr) Marqueurs du syndrome de fatigue chronique
Dean Dissecting the syndrome of schizophrenia: progress toward clinically useful biomarkers
CN104232650A (zh) 特发性基底节钙化新的致病基因及其编码蛋白质和应用
WO2011041725A2 (fr) Biomarqueurs de réponse à un traitement de la schizophrénie
El Khateeb et al. Expression of miR-146a and miR-155 in Egyptian patients with Behçet’s disease: clinical significance and relationship with disease activity
Arisi et al. Cladribine and ocrelizumab induce differential miRNA profiles in peripheral blood mononucleated cells from relapsing–remitting multiple sclerosis patients
NL2025782B1 (en) Novel biomarkers for use in stroke diagnosis and prognosis
CN111971561A (zh) 同种异体移植受体分型的生物标记物
US10155008B2 (en) Use of 15 male fertility related proteins or combination thereof
Unlu et al. Investigation of miR-146a expression profiles in fecal samples of patients with multiple sclerosis for early diagnosis and treatment

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17865027

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17865027

Country of ref document: EP

Kind code of ref document: A1